KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Depreciation and Depletion (2024 - 2026)

Medtronic (MDT) has disclosed Depreciation and Depletion for 3 consecutive years, with $308.0 million as the latest value for Q1 2026.

  • Quarterly Depreciation and Depletion rose 14.93% to $308.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Jan 2026, changed N/A year-over-year, with the annual reading at $1.1 billion for FY2025, 15.3% up from the prior year.
  • Depreciation and Depletion hit $308.0 million in Q1 2026 for Medtronic, up from $282.0 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $322.0 million in Q2 2025 to a low of $248.0 million in Q3 2024.
  • Historically, Depreciation and Depletion has averaged $282.7 million across 3 years, with a median of $282.0 million in 2025.
  • Biggest YoY gain for Depreciation and Depletion was 16.53% in 2025; the steepest drop was 7.63% in 2025.
  • Year by year, Depreciation and Depletion stood at $262.0 million in 2024, then grew by 7.63% to $282.0 million in 2025, then rose by 9.22% to $308.0 million in 2026.
  • Business Quant data shows Depreciation and Depletion for MDT at $308.0 million in Q1 2026, $282.0 million in Q4 2025, and $289.0 million in Q3 2025.